Lakefront Biotherapeutics (LKFT) Common Equity (2014 - 2026)

Lakefront Biotherapeutics (LKFT) has 13 years of Common Equity data on file, last reported at $3.8 billion in Q1 2026.

• Common Equity for Q1 2026 came in at $3.8 billion, up 31.77% year-over-year; the trailing twelve-month figure through Mar 2026 was $3.8 billion (up 31.77% YoY), and the FY2025 annual result was $3.8 billion, up 21.68% from the prior year.
• Common Equity advanced to $3.8 billion in Q1 2026 per LKFT's latest filing, from $3.8 billion in the prior quarter.
• Over five years, Common Equity peaked at $3.8 billion in Q1 2026 and troughed at $2.6 billion in Q4 2022.
• A 5-year average of $3.1 billion and a median of $3.0 billion in 2025 frame the typical range for Common Equity.
• The sharpest annual moves came in 2022 and 2026: Common Equity dropped 14.77% in 2022, then jumped 31.77% in 2026.
• A 5-year view of Common Equity shows it stood at $2.6 billion in 2022, then gained by 16.71% to $3.0 billion in 2023, then climbed by 2.92% to $3.1 billion in 2024, then increased by 21.68% to $3.8 billion in 2025, then advanced by 1.12% to $3.8 billion in 2026.
• Business Quant data shows LKFT's Common Equity at $3.8 billion in Q1 2026, $3.8 billion in Q4 2025, and $2.9 billion in Q3 2025.